Small bowel sarcoma: Tumor biology and advances in therapeutics.
Spindle cell neoplasms are rare mesenchymal tumors of the gastrointestinal tract. GIST (Gastrointestinal stromal tumor) and leiomyosarcoma share similar clinical presentations, gross and microscopic characteristics making distinction difficult in the absence of immunohistochemical (IHC) studies. A multidisciplinary approach is required for treatment planning and ensuring best outcomes. Surgery remains the mainstay of curative treatment for both tumors. Significant advances in targeted molecular therapies have occurred in the past decade in the treatment of GIST with improvement in morbidity and mortality. Similar newer discoveries for treatment of leiomyosarcoma have failed to show any significant survival benefits as yet. Early diagnosis and R0 surgical resection offers the best long term outcome for leiomyosarcoma. Here in we review and discuss the concepts of genetic alterations, newer markers, possible cancer pathways and advances in treatment strategies for these sarcomas.
Department of Surgery, KCVA and University of Missouri Kansas City, 4801 E Linwood Blvd, Kansas City, MO 64128, USA. Electronic address: shenoy2009@hotmail.com.
Santosh
S
Shenoy
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D058990:Molecular Targeted Therapy; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
D000970:Antineoplastic Agents
GIST; Leiomyosarcoma; Signaling pathways; Small bowel; Surgery; Targeted therapies